Visual Acuity Outcome over Time in Non-Infectious Uveitis

Maxwell Pistilli; Marshall M Joffe; Sapna S Gangaputra; Siddharth S Pujari; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; H Nida Sen; Eric B Suhler; Jennifer E Thorne; Nirali P Bhatt; C Stephen Foster; Hosne Begum; Tonetta D Fitzgerald; Kurt A Dreger; Michael M Altaweel; Janet T Holbrook; John H Kempen; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group

doi:10.1080/09273948.2019.1687733

Visual Acuity Outcome over Time in Non-Infectious Uveitis

Ocul Immunol Inflamm. 2021 Aug 18;29(6):1064-1071. doi: 10.1080/09273948.2019.1687733. Epub 2019 Dec 10.

Authors

Maxwell Pistilli^{1

2}, Marshall M Joffe³, Sapna S Gangaputra⁴, Siddharth S Pujari⁵, Douglas A Jabs^{6

7

8}, Grace A Levy-Clarke^{9

10}, Robert B Nussenblatt⁸, James T Rosenbaum^{10

11}, H Nida Sen⁸, Eric B Suhler^{10

11

12}, Jennifer E Thorne^{6

13}, Nirali P Bhatt¹, C Stephen Foster^{14

15}, Hosne Begum¹³, Tonetta D Fitzgerald¹, Kurt A Dreger^{1

13}, Michael M Altaweel^{16

17}, Janet T Holbrook^{6

18}, John H Kempen^{15

19

20}; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group

Affiliations

¹ The Scheie Eye Institute, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
² The Center for Preventive Ophthalmology and Biostatistics, Department of Ophthalmology, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
³ The Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
⁴ Department of Ophthalmology and Vision Sciences, Vanderbilt Eye Institute, Nashville, TN, USA.
⁵ Om Eye Care Hospital, Belgaum, India.
⁶ Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
⁷ Departments of Ophthalmology and Medicine, The Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁸ Laboratory of Immunology, National Eye Institute, Bethesda, MD, USA.
⁹ Tampa Bay Uveitis Center, Tampa, FL, USA.
¹⁰ Department of Ophthalmology, Oregon Health and Science University, Portland, OR, USA.
¹¹ Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
¹² Ophthalmology Service, Portland Veteran's Affairs Medical Center, Portland, OR, USA.
¹³ Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
¹⁴ Massachusetts Eye Research and Surgery Institution, Cambridge, MA, USA.
¹⁵ Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
¹⁶ The Fundus Photograph Reading Center, University of Wisconsin School of Medicine, Madison, WI, USA.
¹⁷ Department of Ophthalmology and Vision Sciences, University of Wisconsin School of Medicine, Madison, WI, USA.
¹⁸ Center for Clinical Trials and Synthesis, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
¹⁹ Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
²⁰ MCM Eye Unit, MCM General Hospital and MyungSung Medical School, Addis Ababa, Ethiopia.

Abstract

Introduction: We evaluated visual acuity (VA) over 5 years in a subspecialty noninfectious uveitis population.Methods: Retrospective data from 5,530 noninfectious uveitis patients with anterior, intermediate, posterior or panuveitis were abstracted by expert reviewers. Mean VA was calculated using inverse probability of censoring weighting to account for losses to follow-up.Results: Patients were a median of 41 years old, 65% female, and 73% white. Initial mean VA was worse among panuveitis (20/84) than posterior (20/64), intermediate (20/47), and anterior (20/37) uveitides. On average, mean VA improved by 0.62, 0.51, 0.37, and 0.26 logMAR-equivalent lines over 2 years, respectively (each P < .001), then remained stable, except posterior uveitis mean VA worsened to initial levels.Conclusion: Mean VA of uveitic eyes improved and, typically, improvement was sustained under uveitis subspecialty care. Because VA tends to improve under tertiary care, mean VA change appears a better outcome for clinical studies than time-to-loss of VA.

Keywords: Uveitis; Visual acuity; inverse probability of censoring weighting.

MeSH terms

Adolescent
Adult
Aged
Female
Humans
Immunosuppressive Agents / therapeutic use
Male
Middle Aged
Retrospective Studies
Tertiary Healthcare
Time Factors
Uveitis / drug therapy
Uveitis / physiopathology*
Visual Acuity / physiology*
Young Adult

Substances

Immunosuppressive Agents

Abstract

MeSH terms

Substances

Grants and funding